Drug-Resistant Melanoma Acquires Exploitable Vulnerability
Source: Genetic Engineering & Biotechnology News, June 2018 Cancer cells that develop resistance to one or more drugs will simultaneously develop a new weakness that could feasibly make them...
View ArticleNew treatment strategy exploits acquired vulnerability in drug-resistant...
Source: Medical Xpress, June 2018 Cancer cells that develop resistance to drugs pay a price for this by simultaneously developing a new vulnerability. If this acquired vulnerability can be identified,...
View ArticleCancer-killing viruses show promise and draw billion-dollar investment
Source: Nature, June 2018 Pharmaceutical giant Johnson & Johnson announced on 2 May that it would pay up to US$1 billion to acquire a company that makes cancer-killing viruses. It was a striking...
View ArticleBlood test for deadly uveal cancer of the eye gives new hope to patients...
Source: ABC News, June 2018 Uveal cancer is a particularly lethal from of the disease. In about half of all cases, the tumour will spread to other parts of a patient’s body. Every year about 250...
View ArticleASCO 2018: PET imaging may top CT in predicting therapy response in melanoma...
Source: Health Imaging, June 2018 PET imaging may better predict long-term benefits and guide discontinuation of therapy compared to standard contrast CT for patients with metastatic melanoma,...
View ArticleNew guidelines help some sufferers of melanoma avoid invasive treatment
Source: ABC Net, June 2018 Sweeping changes have been made to the guidelines used to diagnose and treat melanoma, reflecting the dramatic progress that has been made in the last decade. read the...
View ArticleWhat Surveillance Testing Should Be Done After Melanoma Diagnosis?
Source: Medical Research, June 2018 MedicalResearch.com: What is the background for this study? What are the main findings? Response: The optimal surveillance strategy to detect recurrence in cutaneous...
View ArticleNivolumab More Effective Than Ipilimumab in Resected High-Risk Melanoma
Source: Cancer Network, June 2018 Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab compared with ipilimumab in patients with stage III and IV resected...
View ArticleBMS’ Opdivo cuts risk of melanoma recurrence
Source: Pharma Times, June 2018 Bristol-Myers Squibb’s Opdivo, which is being investigated as adjuvant treatment after surgery for stage IIIb/c or IV melanoma patients at high risk of recurrence, may...
View ArticleLatest AJCC Edition Staging System May Not Be As Effective in Differentiating...
Source: Cancer Therapy Advisor, June 2018 An external validation of the American Joint Committee on Cancer (AJCC) 8th edition staging system found that the latest edition maintained a similar...
View Article
